10 drugs have been suspended from procurement qualifications, involving enterprises like Shu Tai Shen and Paili Pharmaceuticals.

According to the news from Shanghai Sunshine Pharmaceutical Procurement Network on September 15th, the Shanghai Municipal Pharmaceutical Centralized Bidding and Procurement Affairs Management Office issued a notice stating that based on relevant documents from the National Medical Security Administration, some companies have not adjusted drug prices as required. Starting from 0:00 on September 16, 2025, the procurement qualifications for some drugs will be temporarily suspended. This time, a total of 10 drugs with 15 specifications have been suspended from procurement qualifications, involving 11 companies including ShuTaishen Biopharmaceutical Co., Ltd. and Sichuan Bally Pharmaceutical Co., Ltd.